share_log

CVS Health | 8-K: Current report

CVS Health | 8-K: Current report

西維斯健康 | 8-K:重大事件
美股SEC公告 ·  12/06 02:35

Moomoo AI 已提取核心訊息

On December 3, 2024, CVS Health entered into an Underwriting Agreement with Barclays, Citigroup, and Goldman Sachs to issue $3 billion in Junior Subordinated Notes. The issuance includes $2.25 billion of 7.000% Series A Notes due 2055 and $750 million of 6.750% Series B Notes due 2054.The sale is expected to close on December 10, 2024, subject to customary conditions. Net proceeds, after underwriters' discounts and expenses, are estimated at approximately $2.96 billion. The Notes are offered under CVS Health's Registration Statement on Form S-3ASR.Forward-looking statements in the report highlight potential risks and uncertainties. CVS Health advises caution in relying on these statements, as actual results may differ materially due to various factors outlined in their SEC filings.
On December 3, 2024, CVS Health entered into an Underwriting Agreement with Barclays, Citigroup, and Goldman Sachs to issue $3 billion in Junior Subordinated Notes. The issuance includes $2.25 billion of 7.000% Series A Notes due 2055 and $750 million of 6.750% Series B Notes due 2054.The sale is expected to close on December 10, 2024, subject to customary conditions. Net proceeds, after underwriters' discounts and expenses, are estimated at approximately $2.96 billion. The Notes are offered under CVS Health's Registration Statement on Form S-3ASR.Forward-looking statements in the report highlight potential risks and uncertainties. CVS Health advises caution in relying on these statements, as actual results may differ materially due to various factors outlined in their SEC filings.
2024年12月3日,CVS Health與巴克萊、花旗集團和高盛簽訂了承保協議,發行30億美元的初級次級票據。本次發行包括2055年到期的22.5億美元7.000%的A系列票據和2054年到期的7.5億美元6.750%的b系列票據。此次銷售預計將於2024年12月10日結束,但須遵守慣例。扣除承銷商折扣和支出後的淨收益估計約爲29.6億美元。這些票據是在 CVS Health 的 S-3ASR 表格註冊聲明下提供的。報告中的前瞻性陳述突顯了潛在的風險和不確定性。CVS Health建議謹慎依賴這些陳述,因爲由於美國證券交易委員會文件中概述的各種因素,實際結果可能會有重大差異。
2024年12月3日,CVS Health與巴克萊、花旗集團和高盛簽訂了承保協議,發行30億美元的初級次級票據。本次發行包括2055年到期的22.5億美元7.000%的A系列票據和2054年到期的7.5億美元6.750%的b系列票據。此次銷售預計將於2024年12月10日結束,但須遵守慣例。扣除承銷商折扣和支出後的淨收益估計約爲29.6億美元。這些票據是在 CVS Health 的 S-3ASR 表格註冊聲明下提供的。報告中的前瞻性陳述突顯了潛在的風險和不確定性。CVS Health建議謹慎依賴這些陳述,因爲由於美國證券交易委員會文件中概述的各種因素,實際結果可能會有重大差異。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息